Seong Joon Ahn1, Se Joon Woo, Ko Eun Kim, Kyu Hyung Park. 1. Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Abstract
PURPOSE: To investigate associations between outcome of anti-vascular endothelial growth factor (VEGF) therapy and choroidal morphology in eyes with myopic choroidal neovascularization (CNV). METHODS: Fifty-two eyes of 46 patients with myopic CNV received a single intravitreal anti-VEGF injection, followed by as-needed injections. Baseline choroidal thickness was measured at the fovea and 1.5 and 3 mm nasal, temporal, superior, and inferior to the fovea using enhanced depth imaging optical coherence tomography. Measurements were compared between eyes with and without CNV resolution after a single injection and between those with and without CNV recurrence within 1 year of initial injection. Associations between treatment outcomes and morphologic or clinical factors were assessed using regression analyses. RESULTS: Patients received 1.8 ± 1.3 intravitreal injections during follow-up. Eyes with CNV resolution after a single anti-VEGF injection had a significantly thicker inferior choroid than those without resolution (67.3 ± 32.9 vs. 44.5 ± 17.6 μm, P = 0.002). The subfoveal choroid was thinner in eyes with recurring CNV than in those without recurrence (35.7 ± 23.7 vs. 52.0 ± 20.8 μm, P = 0.029). Associations were found between inferior choroidal thickness and CNV resolution (P = 0.019) and between subfoveal choroidal thickness and 1-year recurrence rates (P = 0.016). Adjusted odds ratios were 9.1 for CNV resolution with an inferior choroidal thickness >49 μm and 5.6 for recurrence within 1 year with a subfoveal choroidal thickness ≤47.5 μm. CONCLUSIONS: A thinner subfoveal/inferior choroid at baseline may indicate poor anatomic outcome after intravitreal anti-VEGF treatment in eyes with myopic CNV.
PURPOSE: To investigate associations between outcome of anti-vascular endothelial growth factor (VEGF) therapy and choroidal morphology in eyes with myopic choroidal neovascularization (CNV). METHODS: Fifty-two eyes of 46 patients with myopic CNV received a single intravitreal anti-VEGF injection, followed by as-needed injections. Baseline choroidal thickness was measured at the fovea and 1.5 and 3 mm nasal, temporal, superior, and inferior to the fovea using enhanced depth imaging optical coherence tomography. Measurements were compared between eyes with and without CNV resolution after a single injection and between those with and without CNV recurrence within 1 year of initial injection. Associations between treatment outcomes and morphologic or clinical factors were assessed using regression analyses. RESULTS:Patients received 1.8 ± 1.3 intravitreal injections during follow-up. Eyes with CNV resolution after a single anti-VEGF injection had a significantly thicker inferior choroid than those without resolution (67.3 ± 32.9 vs. 44.5 ± 17.6 μm, P = 0.002). The subfoveal choroid was thinner in eyes with recurring CNV than in those without recurrence (35.7 ± 23.7 vs. 52.0 ± 20.8 μm, P = 0.029). Associations were found between inferior choroidal thickness and CNV resolution (P = 0.019) and between subfoveal choroidal thickness and 1-year recurrence rates (P = 0.016). Adjusted odds ratios were 9.1 for CNV resolution with an inferior choroidal thickness >49 μm and 5.6 for recurrence within 1 year with a subfoveal choroidal thickness ≤47.5 μm. CONCLUSIONS: A thinner subfoveal/inferior choroid at baseline may indicate poor anatomic outcome after intravitreal anti-VEGF treatment in eyes with myopic CNV.
Authors: Ki Woong Bae; Dong Ik Kim; Bo Hee Kim; Baek-Lok Oh; Eun Kyoung Lee; Chang Ki Yoon; Un Chul Park Journal: PLoS One Date: 2022-09-22 Impact factor: 3.752